
簡要描述:Recombinant Rat GM-CSF Protein,Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine FDC-P1 is less than 0.01 ng/ml, corresponding to a
產品分類
Product Category詳細介紹
| 品牌 | absin | 純度 | > 98 % |
|---|---|---|---|
| 貨號 | abs01067 | 規(guī)格 | 5ug |
| 供貨周期 | 現貨 | 主要用途 | Lyophilized from a 0.2 μm filtered solut |
| 應用領域 | 化工,生物產業(yè),農林牧漁,制藥/生物制藥,綜合 |
Recombinant Rat GM-CSF Protein
| 概述 | |
| 別名 | GM-CSF蛋白;CSF2蛋白 |
| 種屬 | Rat |
| 來源 | Escherichia coli. |
| 形態(tài) | Lyophilized from a 0.2 μm filtered solution in PBS, pH 7.4. |
| 性能 | |
| 序列 | APTRSPNPVT RPWKHVDAIK EALSLLNDMR ALENEKNEDV DIISNEFSIQ RPTCVQTRLK LYKQGLRGNL TKLNGALTMI ASHYQTNCPP TPETDCEIEV TTFEDFIKNL KGFLFDIPFD CWKPVQK |
| 標簽 | No Tag |
| 純度 | > 98 % by SDS-PAGE and HPLC analyses. |
| 內毒素水平 | Less than 1 EU/μg of rRtGM-CSF as determined by LAL method. |
| 活性 | Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine FDC-P1 is less than 0.01 ng/ml, corresponding to a specific activity of > 1.0 × 108 IU/mg. |
| 溶解方法 | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| 儲存/保存方法 | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 靶標 | |
| Accession | P48750 |
| Gene IDs | 116630 |
| 參考文獻 | |
| 參考文獻 | 1. Wang JM, Chen ZG, Colotta F, et al. 1988. Behring Inst Mitt: 270-3. 2. 1989. N Engl J Med, 320: 253-4. 3. Nissen-Druey C. 1989. Nouv Rev Fr Hematol, 31: 99-101. 4. Eager RandNemunaitis J. 2005. Mol Ther, 12: 18-27. 5. Tran T, Fernandes DJ, Schuliga M, et al. 2005. Br J Pharmacol, 145: 123-31. |
產品咨詢
